Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12357268 | 0.95 | CYP2A6 (0.59) | CYP2A6CYP1A2TDP1ACHERAB9A | |
| SCHEMBL7750 | 0.95 | CYP2A6 (0.65) | CYP2A6CYP1A2TDP1ACHERAB9A | |
| SCHEMBL443528 | 0.88 | CYP2A6 (0.80) | CYP2A6CYP1A2RAB9AHSD17B1HSD17B2 | |
| SCHEMBL29367032 | 0.88 | CYP2A6 (0.80) | CYP2A6CYP1A2RAB9AHSD17B1HSD17B2 | |
| SCHEMBL15869806 | 0.87 | CYP2A6 (0.54) | CYP2A6CYP1A2TDP1ACHEFLT3 | |
| SCHEMBL12031848 | 0.87 | HSD17B1 (0.68) | CYP2A6CYP1A2ACHERAB9AFLT3 | |
| SCHEMBL26710972 | 0.85 | CYP2A6 (0.52) | CYP2A6CYP1A2TDP1ACHEFLT3 | |
| SCHEMBL12054396 | 0.84 | CYP2A6 (0.67) | CYP2A6CYP1A2TDP1ACHERAB9A | |
| SCHEMBL12054398 | 0.84 | CYP2A6 (0.67) | CYP2A6CYP1A2TDP1ACHERAB9A | |
| SCHEMBL13241091 | 0.84 | HSD17B1 (0.63) | CYP2A6CYP1A2ACHERAB9AHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-20220389027-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2022-12-08 | — | — | US | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3582789-B1 | MULTIVALENT FUCOSE DERIVATIVES FOR USE AS A DRUG | UNIV NANTES (FR) | 2022-06-22 | — | — | EP | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| WO-2020121577-A1 | EPOXY COMPOUND | JNC株式会社 | 2020-06-18 | — | — | WO | disclosed |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-07 | — | — | US | disclosed |
| EP-2966077-B1 | CHALCOGEN-CONTAINING ORGANIC COMPOUND AND USE THEREFOR | JNC CORP (JP) | 2020-04-01 | — | — | EP | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | disclosed |
| US-5958918-A | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. | 1999-09-28 | — | — | US | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0201201-B1 | AMIDO SUBSTITUTED DIVALENT CHALCOGENIDE FOG INHIBITING AGENTS FOR SILVER HALIDE PHOTOGRAPHY | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0149588-A2 | N-(naphthyl-alkyl)-hydroxylamines | SANDOZ AG (CH) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | CYP2A6 4059/4885CYP1A2 3639/4885TDP1 707/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP2A6 1430/4885CYP1A2 572/4885TDP1 2750/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | CYP2A6 1601/4885CYP1A2 1023/4885TDP1 1502/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | CYP2A6 4059/4885CYP1A2 3639/4885TDP1 707/4885 |
| US-20220389027-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | CRY1, CCNA1, CRY2 | CYP2A6 438/4885CYP1A2 28/4885TDP1 3498/4885 |
| US-20200140436-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | F12, F2, CPB1 | CYP2A6 1025/4885CYP1A2 1188/4885TDP1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.